• PDF / 169,516 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 83 Downloads / 126 Views

DOWNLOAD

REPORT

---

1 S

Sirolimus/propranolol Oral mucositis and rebound effect: case report

In a monocentric and observational study in a single-center patient cohort involving 20 children treated for infantile hepatic hemangioendothelioma (IHHE) in Shanghai Children’s Medical Center between December 2017 and April 2019, a child [age and sex not stated] was described, who experienced rebound effect during treatment with propranolol and grade III oral mucositis during treatment with sirolimus for IHHE. The child, who had IHHE, initially received treatment with oral propranolol (10 mg/piece) 1 mg/kg for twenty months with good response. Subsequently, propranolol was discontinued, and the IHHE rebounded. Hence, the child was given unspecified hormonal therapy. But, no improvement was noted. Therefore, the child was started on sirolimus (1 mg/mL) 0.8 mg/m2 per body surface area, every 12 hours [route not stated]. Subsequently, the child developed grade III oral mucositis related to sirolimus [duration of treatment to reaction onset not stated]. Therefore, the child’s family discontinued the sirolimus treatment [outcome not stated]. Tian R, et al. Propranolol for infantile hepatic hemangioendothelioma: Clinical evaluation of drug efficacy and safety using a single-center patient cohort. Annals of Hepatology 19: 530-534, No. 5, Oct 2020. Available from: URL: http://doi.org/10.1016/j.aohep.2020.04.008

0114-9954/20/1830-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

803514511

Reactions 14 Nov 2020 No. 1830